Kyle Fedorchak
Foundation Medicine
7 Papers
2 Citations
Kyle Fedorchak is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Loss of heterozygosity in multiple myeloma: A role for PARP inhibition?
Charlotte Pawlyn,Andrea Loehr,Ruslana Tytarenko,Shayu Deshpande,James Sun,Kyle Fedorchak,Tariq I Mughal,Faith E. Davies,Brian A Walker,Mitch Raponi,Gareth J. Morgan +10 more
TL;DR: It is hypothesized that LOH could be detected in patient samples, supporting a potential role for PARP inhibition in MM, and an algorithm using the minor allele frequencies of the examined SNPs and copy number profile across the 22 autosomal chro...
2
Genomic characterization of high-risk non-muscle invasive bladder cancer.
Joshua J. Meeks,Benedito A. Carneiro,Sachin Gopalkrishna Pai,Daniel T. Oberlin,Alfred Rademaker,Kyle Fedorchak,Sohail Balasubramanian,Julia A. Elvin,Nike Beaubier,Francis J. Giles +9 more
TL;DR: No novel genetic drivers in progressors and HR-NMIBC had many genetic features similar to metastatic BC, and loss of CDKN2A/B locus as a biomarker for progression of NMIBC is found.
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Charlotte Pawlyn,Andrea Loehr,Cody Ashby,Ruslana Tytarenko,Shayu Deshpande,James Sun,Kyle Fedorchak,Tariq I Mughal,Faith E. Davies,Brian A Walker,Gareth J. Morgan +10 more
TL;DR: HRD-LOH is demonstrated in MM samples, increasing as disease progresses, and further evaluation of PARP inhibitors in MM patients, particularly in the relapsed setting with a high unmet need for new treatments is supported.
Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer.
Douglas A. Mata,L. Harries,G. Williams,Matthew C. Hiemenz,Brennan Decker,Julie Y. Tse,Tyler Janovitz,Donna C. Ferguson,Iain A Speece,Matthew Margolis,Benjamin Mathews,Kyle Fedorchak,J. Keith Killian,Jinpeng Xiao,Khaled A. Tolba,Shakti Ramkissoon,Jo-Anne Vergilio,Julia A. Elvin,Geoffrey R. Oxnard,Jeffrey S. Ross,Richard Huang +20 more
TL;DR: The method of tissue acquisition was an important preanalytic factor that determined whether a sample would be successfully sequenced and whether a clinically actionable genomic alteration would be detected in lung cancer.